144 related articles for article (PubMed ID: 19827050)
1. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
Nadiminty N; Dutt S; Tepper C; Gao AC
Prostate; 2010 Feb; 70(3):276-87. PubMed ID: 19827050
[TBL] [Abstract][Full Text] [Related]
2. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
Nadiminty N; Chun JY; Lou W; Lin X; Gao AC
Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells.
Lessard L; Saad F; Le Page C; Diallo JS; Péant B; Delvoye N; Mes-Masson AM
Cell Signal; 2007 May; 19(5):1093-100. PubMed ID: 17292587
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Seo SI; Song SY; Kang MR; Kim MS; Oh JE; Kim YR; Lee JY; Yoo NJ; Lee SH
APMIS; 2009 Aug; 117(8):623-8. PubMed ID: 19664134
[TBL] [Abstract][Full Text] [Related]
7. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
8. Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells.
Kumagai T; Tomari K; Shimizu T; Takeda K
Int J Mol Med; 2006 Feb; 17(2):285-91. PubMed ID: 16391828
[TBL] [Abstract][Full Text] [Related]
9. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Fujinami K; Uemura H; Ishiguro H; Kubota Y
Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
[TBL] [Abstract][Full Text] [Related]
10. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
11. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.
Grzmil M; Voigt S; Thelen P; Hemmerlein B; Helmke K; Burfeind P
Int J Oncol; 2004 Jan; 24(1):97-105. PubMed ID: 14654946
[TBL] [Abstract][Full Text] [Related]
12. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
13. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H
Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627
[TBL] [Abstract][Full Text] [Related]
14. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.
Ngan S; Stronach EA; Photiou A; Waxman J; Ali S; Buluwela L
Oncogene; 2009 May; 28(19):2051-63. PubMed ID: 19363526
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.
Spurgers KB; Coombes KR; Meyn RE; Gold DL; Logothetis CJ; Johnson TJ; McDonnell TJ
Oncogene; 2004 Mar; 23(9):1712-23. PubMed ID: 14647426
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
17. Analysis of differentially expressed genes in LNCaP prostate cancer progression model.
Xie BX; Zhang H; Wang J; Pang B; Wu RQ; Qian XL; Yu L; Li SH; Shi QG; Huang CF; Zhou JG
J Androl; 2011; 32(2):170-82. PubMed ID: 20864652
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
19. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.
Wolfgang CD; Essand M; Lee B; Pastan I
Cancer Res; 2001 Nov; 61(22):8122-6. PubMed ID: 11719440
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
